Recent developments in the management of severe asthma

Howraman Meteran; Louise Lindhardt Tønnesen; Pradeesh Sivapalan; Truls Sylvan Ingebrigtsen; Jens-Ulrik Stæhr Jensen

doi:10.1183/20734735.0178-2021

Recent developments in the management of severe asthma

Breathe (Sheff). 2022 Mar;18(1):210178. doi: 10.1183/20734735.0178-2021. Epub 2022 May 10.

Authors

Howraman Meteran^{1

2

3}, Louise Lindhardt Tønnesen^{1

4}, Pradeesh Sivapalan^{1

5}, Truls Sylvan Ingebrigtsen¹, Jens-Ulrik Stæhr Jensen^{1

6}

Affiliations

¹ Dept of Internal Medicine, Respiratory Medicine Section, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
² Dept of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
³ Dept of Public Health, Environment, Work and Health, Aarhus University, Aarhus, Denmark.
⁴ Dept of Respiratory Medicine, Copenhagen University Hospital, Hvidovre, Denmark.
⁵ Dept of Internal Medicine, Zealand Hospital, University of Copenhagen, Roskilde, Denmark.
⁶ Dept of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Abstract

Fevipiprant is unlikely to be implemented as a future treatment for severe asthma, while tezepelumab may be a future treatment option for patients with severe asthma with and without eosinophilic inflammation https://bit.ly/3KE1BH4.